Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
The feature you requested does not exist. However, we suggest the following feature:

Findings in Atopic Dermatitis Reported from Novartis (Impact of chronic urticaria on quality of life and work in Japan: Results of a real-world study)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/21/2018 | 11:14pm CEST

By a News Reporter-Staff News Editor at Pharma Business Week -- Investigators publish new report on Skin Diseases and Conditions - Atopic Dermatitis. According to news reporting from Tokyo, Japan, by NewsRx journalists, research stated, "Little attention has been given to the burden of chronic urticaria (CU) in Japan compared with other skin diseases, such as atopic dermatitis (AD) and psoriasis. The primary objective of the RELEASE study was to evaluate the real-life quality-of-life impairment in CU patients in Japan."

Financial support for this research came from Novartis Pharma K.K., Tokyo, Japan (see also Skin Diseases and Conditions - Atopic Dermatitis).

The news correspondents obtained a quote from the research from Novartis, "Data were collected from 1443 urticaria, 1668 AD and 435 psoriatic patients; 552 urticaria patients who presented urticaria symptoms for over 6 weeks were defined as CU. The mean Dermatology Life Quality Index (DLQI) total score was 4.8, 6.1 and 4.8 in CU, AD and psoriatic patients, respectively. Disease control of urticaria evaluated by the Urticaria Control Test (UCT) and DLQI exhibited a strong correlation with a Spearman's rank correlation coefficient of -0.7158. CU and AD patients had relatively higher scores in all Work Productivity and Activity Impairment -General Health subscales except for absenteeism. At the time of the survey, approximately 64% of CU patients reported UCT scores of <12 and demonstrated higher work productivity loss and activity impairment versus patients with UCT scores of greater than or equal to12. Patients with lower UCT scores also displayed a higher percentage of dissatisfaction with their health state and the treatment they received. Approximately 85% of patients with CU had visited dermatology clinics, and less than 20% had visited hospital, indicating existence of a highly burdened population outside specialized centers."

According to the news reporters, the research concluded: "These results highlight the unmet medical needs of CU patients, suggesting the need to increase awareness of CU burden among both physicians and patients and to pursue improved real-life patient care."

For more information on this research see: Impact of chronic urticaria on quality of life and work in Japan: Results of a real-world study. The Journal of Dermatology, 2018;():. The Journal of Dermatology can be contacted at: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA.

Our news journalists report that additional information may be obtained by contacting A. Itakura, Novartis Pharma K.K., Tokyo, Japan. Additional authors for this research include Y. Tani, N. Kaneko and M. Hide.

Publisher contact information for the The Journal of Dermatology is: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA.

Keywords for this news article include: Pharmaceutical Companies, Tokyo, Business, Urticaria, Dermatology, Quality of Life, Atopic Dermatitis, Health and Medicine, Immediate Hypersensitivity, Vascular Skin Diseases and Conditions.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC

(c) 2018 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
06/21FINDINGS IN ATOPIC DERMATITIS REPORT : Results of a real-world study)
AQ
06/21NOVARTIS : New Multiple Myeloma Findings Reported from Novartis [Pre-clinical va..
AQ
06/21NOVARTIS : JULIET trial of Kymriah demonstrates more than one-year durability of..
AQ
06/20GLOBAL CARCINOID SYNDROME MANAGEMENT : The research provide Industry Overview, M..
AQ
06/20NOVARTIS : survey uncovers real-world impact of immune thrombocytopenia or ITP, ..
AQ
06/20NOVARTIS : study of real-world data concludes Jakavi is associated with a reduct..
AQ
06/20NOVARTIS : Sandoz presents new long-term and switching data for biosimilars Zess..
AQ
06/19Payers, drugmakers face off over CAR T Medicare coverage
AQ
06/18NOVARTIS : JULIET Trial of Kymriah Demonstrates More Than One-Year Durability of..
AQ
06/18NOVARTIS INTERNATIONAL AG : Alcon AcrySof IQ PanOptix Trifocal Intraocular Lens ..
AQ
More news
News from SeekingAlpha
06/21Neon Therapeutics Firms Its Plan For $100 Million IPO 
06/21Forty Seven Readies $100 Million U.S. IPO 
06/20YOUR DAILY PHARMA SCOOP : TG Therapeutics Phase 2 Results, Geron Positive, Agio .. 
06/19Translate Bio Prepares For $100 Million U.S. IPO 
06/19Sandoz Canada to enter medical cannabis arena 
Financials ($)
Sales 2018 52 590 M
EBIT 2018 13 229 M
Net income 2018 10 415 M
Debt 2018 13 548 M
Yield 2018 4,00%
P/E ratio 2018 15,39
P/E ratio 2019 18,26
EV / Sales 2018 3,83x
EV / Sales 2019 3,68x
Capitalization 188 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 90,1 $
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-10.17%188 057
JOHNSON & JOHNSON-12.27%328 751
PFIZER0.00%211 871
ROCHE HOLDING LTD.-12.19%183 625
MERCK AND COMPANY8.90%164 189
AMGEN7.07%123 203